Cartesian Therapeutics (RNAC) Daily Performance Summary
Trading Session
- Date: Friday, 23 Feb 2026 (24‑hour period ending 06:32 PM CET)
- Closing price: USD 6.21
- Percentage change: ‑0.16 %
Key Market Metrics
| Metric | Value |
|---|---|
| Shares outstanding | 30.3 million |
| Market capitalization | USD 194.2 million |
| 24‑hour trading volume | USD 571.8 k |
| 1‑month change | ‑18.55 % |
| 200‑day simple moving average | USD 7.69 |
| 52‑week high | USD 11.00 (24 Jun 2026) |
| 52‑week low | USD 5.60 (27 Mar 2026) |
Cartesian Therapeutics’ share price remains below its 200‑day moving average and has declined markedly since the previous month’s close.
Performance of Related Companies (24‑Hour Period)
| Ticker | Change | Current Price | Market Cap | Notable Detail |
|---|---|---|---|---|
| LYEL | ‑2.99 % | USD 9.32 | USD 230.6 million | — |
| CMTV | +4.83 % | USD 43.22 | USD 232.1 million | P/E ratio 12.6 |
| IKT | ‑2.92 % | USD 1.58 | USD 231.6 million | Recent filings on executive stock‑option activity (21 Oct 2026). |
| SVCC | ‑0.19 % | USD 10.72 | USD 231.3 million | — |
| SMRT | +1.68 % | USD 1.24 | USD 231.9 million | — |
Company Overview
Cartesian Therapeutics, Inc. is a biotechnology firm headquartered in Watertown, United States. The company specializes in RNA cell‑therapy platforms designed to eliminate pathogenic plasma cells that produce autoantibodies. Its therapeutic pipeline focuses on autoimmune diseases and related conditions.
Summary
Cartesian Therapeutics’ share price has fallen slightly during the reported period and remains below its 200‑day average, reflecting a broader decline of nearly 19 % since the previous month. In contrast, peer company Community /Vt posted a modest gain, while most other comparable biotechnology stocks traded in the negative range. The company’s market capitalization and trading volume indicate moderate liquidity, and its recent price movement is consistent with the sector’s broader volatility.